The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes
Open accessAbstract
Purpose: Human T-cell lymphotropic virus type-I–associated adult T-cell leukemia/lymphoma (ATL) is an aggressive, chemotherapy-resistant malignancy. Multiple small studies using zidovudine (AZT) and interferon-alfa (IFN-α) have shown response in patients with ATL. However, the impact of this innovative antiviral treatment strategy on long-term survival remains undetermined. Patients and Methods: We report a meta-analysis of antiviral therapy of ATL. Medical records of 254 patients with ATL who were treated in the United States, the United Kingdom, Martinique, and continental France were individually reviewed. Results: According to Shimoyama classification, there were 116 patients with acute ATL, 18 patients with chronic ATL, 11 patients with smoldering ATL, and 100 patients with ATL lymphoma. In 231 patients with available survival data, first-line therapy was recorded in 207 patients. Five-year overall survival rates were 46% for 75 patients who received first-line antiviral therapy (P = .004), 20% for 77 patients who received first-line chemotherapy, and 12% for 55 patients who received first-line chemotherapy followed by antiviral therapy. Patients with acute, chronic, and smoldering ATL significantly benefited from first-line antiviral therapy, whereas patients with ATL lymphoma experienced a better outcome with chemotherapy. In acute ATL, achievement of complete remission with antiviral therapy resulted in 82% 5-year survival. Antiviral therapy in chronic and smoldering ATL resulted in 100% 5-year survival. Multivariate analysis confirmed that first-line antiviral therapy significantly improves overall survival of patients with ATL (hazard ratio, 0.47; 95% CI, 0.27 to 0.83; P = .021). Conclusion: These results confirm the high efficacy of AZT and IFN, which should now be considered the gold standard first-line therapy in leukemic subtypes of ATL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608
Hinuma, Y., Komoda, H., Chosa, T., Kondo, T., Kohakura, M., Takenaka, T., Kikuchi, M., Ichimaru, M., Yunoki, K., Sato, I., et al. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910290606 · Cited by 591
Tsukasaki, K., Hermine, O., Bazarbachi, A., Ratner, L., Ramos, J. C., Harrington, W., O’Mahony, D., Janik, J. E., Bittencourt, A. L., Taylor, G. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2428 · Cited by 558
Self-citationTsukasaki, K., Utsunomiya, A., Fukuda, H., Shibata, T., Fukushima, T., Takatsuka, Y., Ikeda, S., Masuda, M., Nagoshi, H., Ueda, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9958 · Cited by 493
Treatment of Adult T-Cell Leukemia–Lymphoma with a Combination of Interferon Alfa and Zidovudine
Gill, P. S., Harrington, W., Kaplan, M. H., Ribeiro, R. C., Bennett, J. M., Liebman, H. A., Bernstein-Singer, M., Espina, B. M., Cabral, L., Allen, S., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322603 · Cited by 372
Self-citationYamada, Y., Tomonaga, M., Fukuda, H., Hanada, S., Utsunomiya, A., Tara, M., Sano, M., Ikeda, S., Takatsuki, K., Kozuru, M., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02737.x · Cited by 354
Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa
Hermine, O., Bouscary, D., Gessain, A., Turlure, P., Leblond, V., Franck, N., Buzyn-Veil, A., Rio, B., Macintyre, E., Dreyfus, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322604 · Cited by 265
Self-citationNew therapeutic approaches for adult T-cell leukaemia
Bazarbachi, A. A., Ghez, D., Lepelletier, Y., Nasr, R., de Thé, H., El-Sabban, M. E., & Hermine, O. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01608-0 · Cited by 141
Self-citationPersistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T. A., Hermine, O., & Nicot, C. (2006) · Blood · doi:10.1182/blood-2006-01-0067 · Cited by 139
Self-citationHermine, O., Allard, I., Lévy, V., Arnulf, B., Gessain, A., & Bazarbachi, A. A. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200195 · Cited by 132
Self-citationAdult T-cell leukemia/lymphoma
Dahmoush, L., Hijazi, Y. M., Barnes, E., Stetler‐Stevenson, M., & Abati, A. D. (2002) · Cancer · doi:10.1002/cncr.10480 · Cited by 124
Epidemiology of HTLV-I and associated diseases
Gessain, A. (1996) · Cited by 95
Self-citationIRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma
Ramos, J. C., Ruiz, P., Ratner, L., dos Reis, I. M., Brites, C. R., Pedroso, C., Byrne, G. E., Toomey, N., Andela, V. B., Harhaj, E. W., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036368 · Cited by 85
Self-citationBazarbachi, A. A., & Hermine, O. (1996) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199600001-00028 · Cited by 75
Self-citationWhite, J. D., Wharfe, G., Stewart, D. M., Maher, V. E., Eicher, D. M., Herring, B., Derby, M., Jackson-Booth, P.-G., Marshall, M. A., Lucy, D., et al. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057927 · Cited by 74
Retrovirus Biology and Human Disease
Wiedemann, H. P., & Proffitt, M. R. (1991) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.58.3.205 · Cited by 68
Bazarbachi, A. A., Nasr, R., El-Sabban, M. E., Mahé, A., Mahieux, R., Gessain, A., Darwiche, N., Dbaibo, G. S., Kersual, J., Zermati, Y., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401742 · Cited by 68
Self-citationMacchi, B., Grelli, S., Favalli, C., Mastino, A., Bonmassar, E., Faraoni, I., & Zhang, J. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-5-1007 · Cited by 66
Feng, X., Heyden, N. V., & Ratner, L. (2003) · Journal of Virology · doi:10.1128/jvi.77.24.13389-13395.2003 · Cited by 62
Adult T Cell Leukaemia: A Review of Established and New Treatments
Hermine, O., Wattel, E., Gessain, A., & Bazarbachi, A. A. (1998) · BioDrugs · doi:10.2165/00063030-199810060-00003 · Cited by 52
Self-citationTakasaki, Y., Iwanaga, M., Tsukasaki, K., Kusano, M., Sugahara, K., Yamada, Y., Kamihira, S., Ikeda, S., & Tomonaga, M. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.11.013 · Cited by 50
Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome
Ramos, M. V. C. C., Fernández, G. C., Patey, N., Schierloh, P., Exeni, R. A., Grimoldi, I., Vallejo, G., Elías-Costa, C., Sasiain, M. D. C., Trachtman, H., et al. (2006) · Blood · doi:10.1182/blood-2006-06-026997 · Cited by 49
Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma
Ratner, L., Harrington, W. J., Feng, X., Grant, C. W., Jacobson, S., Noy, A., Sparano, J. A., Lee, J. Y., Ambinder, R. F., Campbell, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004420 · Cited by 48
Self-citationAntiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits
Isono, T., Ogawa, K., & Seto, A. (1990) · Leukemia Research · doi:10.1016/0145-2126(90)90172-6 · Cited by 43
Advances in adult T-cell leukemia and HTLV-I research
高月, 清., 日沼, 頼., & 吉田, 光. (1992) · Cited by 37
Adult T Cell Leukemia/Lymphoma
Yamaguchi, K., FUTAMI, G., Kiyokawa, T., Ishii, T., Murphy, J. R., & Takatsuki, K. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb33447.x · Cited by 33
Cited by
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“Bazarbachi et al. (2010) reported that azidothymidine (AZT) and IFN-α plus or minus arsenic therapy was associated with a response in the majority of patients with human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATLL).”
BackgroundFoss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011) · Blood · doi:10.1182/blood-2010-05-231548 · Cited by 353
Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma
Ishitsuka, K., & Tamura, K. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70202-5 · Cited by 343
Metadata
- Authors
- Bazarbachi, A., Plumelle, Y., Carlos Ramos, J., Tortevoye, P., Otrock, Z., Taylor, G., Gessain, A., Harrington, W., Panelatti, G., & Hermine, O.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-09-20
- Volume
- 28
- Issue
- 27
- Pages
- 4177-4183
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119092367
- Cited by
- 373
- References
- 26
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.